Stock Analiz

Liminatus Pharma, Inc. LIMN

Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026

$2.99Market cap $4M
Open the interactive analysis →

Liminatus Pharma, Inc. (LIMN) is a healthcare company listed in the US with a market value of about $4M.

Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is track record (1/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -416%.

About Liminatus Pharma

Liminatus Pharma is listed in the US and classified in biotechnology: biological products (no diagnostic substances). It was profitable in 0 of the last 2 years in our data.

Score: 0.2 / 5

Value0/5
Future growth0/5
Track record1/5
Financial health0/5
Shareholder returns0/5

Checks passed

  • ROE above 15%

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B13.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-248.4%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)-415.6%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 2 years

Fiscal year20252024
Revenue——
Net income-$10M-$4M
Free cash flow-$10M—
EPS (diluted)$-0.43$-0.20
Net margin——
ROIC—-415.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Liminatus Pharma pay a dividend?

Not currently.

Is Liminatus Pharma a good stock to buy?

We do not give buy or sell advice. Liminatus Pharma scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.